Clinical Trials Directory

Trials / Conditions / Respiratory Syncytial Virus

Respiratory Syncytial Virus

44 registered clinical trials studyying Respiratory Syncytial Virus3 currently recruiting.

StatusTrialSponsorPhase
RecruitingA Post-marketing Surveillance Study of Beyfortus (Nirsevimab) in Republic of Korea
NCT07200206
Sanofi
Active Not RecruitingPhase II Clinical Trial of Lyophilized Respiratory Syncytial Virus mRNA Vaccine in Adults Aged 50 Years or Abo
NCT07289542
Suzhou Abogen Biosciences Co., Ltd.Phase 2
Active Not RecruitingSTudy of Real World vaccinE Effectiveness of maTernal RSVpreF vaccinatiON Against Respiratory Syncytial Virus
NCT07122661
Pfizer
Active Not RecruitingA Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV)
NCT07117487
ModernaTX, Inc.Phase 3
Active Not RecruitingPhase I Clinical Trial of Lyophilized Respiratory Syncytial Virus mRNA Vaccine in Adults Aged 18 Years or Abov
NCT07289503
Suzhou Abogen Biosciences Co., Ltd.Phase 1
RecruitingA Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Respiratory Syncytial Virus
NCT06754605
Sinocelltech Ltd.Phase 1 / Phase 2
CompletedA Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Older Adults in Korea
NCT06593587
PfizerPhase 3
Active Not RecruitingImpact and Effectiveness of ABRYSVO® Vaccination During Pregnancy
NCT06647654
Pfizer
RecruitingAssessing Antiviral Treatments in Early Symptomatic RSV
NCT06488300
University of OxfordPhase 2
CompletedBEYFORTUS™ (Nirsevimab) Effectiveness Against Medically-Attended RSV Events in Infants (BEAR Study)
NCT06325332
Sanofi Pasteur, a Sanofi Company
CompletedA Study to Learn About the Vaccine RSVpreF In Pregnant Participants With HIV and Their Infants
NCT06325657
PfizerPhase 3
Active Not RecruitingA Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Va
NCT06143046
ModernaTX, Inc.Phase 2
CompletedA Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age
NCT06097299
ModernaTX, Inc.Phase 2
Active Not RecruitingA Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Viru
NCT06067230
ModernaTX, Inc.Phase 3
CompletedA Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Vir
NCT06060457
ModernaTX, Inc.Phase 3
Active Not RecruitingA Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <
NCT05743881
ModernaTX, Inc.Phase 1
CompletedRespiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants (MK-4482-017)
NCT05559905
Merck Sharp & Dohme LLCPhase 2
CompletedModerna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study
NCT05572658
ModernaTX, Inc.
CompletedA Study of Modified mRNA Vaccines in Healthy Adults
NCT05397223
ModernaTX, Inc.Phase 1
CompletedSafety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of Age
NCT05301322
PfizerPhase 3
CompletedA Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age
NCT05330975
ModernaTX, Inc.Phase 3
CompletedA Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) i
NCT05127434
ModernaTX, Inc.Phase 2 / Phase 3
TerminatedA Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection
NCT04978337
Janssen Research & Development, LLCPhase 2
CompletedA Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults
NCT04528719
ModernaTX, Inc.Phase 1
CompletedA Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncyt
NCT04196101
Enanta Pharmaceuticals, IncPhase 2
CompletedA Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory
NCT03606512
Janssen Vaccines & Prevention B.V.Phase 1 / Phase 2
CompletedSafety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002)
NCT03524118
Merck Sharp & Dohme LLCPhase 1 / Phase 2
CompletedDose, Safety, Tolerability and Immunogenicity of a Stabilized Prefusion RSV F Subunit Protein Vaccine, VRC-RSV
NCT03049488
National Institute of Allergy and Infectious Diseases (NIAID)Phase 1
CompletedProspective Pilot Clinical Trial of Azithromycin Treatment In Respiratory Syncytial Virus (RSV)- Induced Respi
NCT02707523
University of Alabama at BirminghamPhase 2
TerminatedA Study to Evaluate the Efficacy of MEDI7510 in Older Adults
NCT02508194
MedImmune LLCPhase 2
CompletedA Study to Evaluate the Safety and Reactogenicity of DPX-RSV(A), a Respiratory Syncytial Virus Vaccine
NCT02472548
Dalhousie UniversityPhase 1
CompletedPresatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper
NCT02254408
Gilead SciencesPhase 2
CompletedA Phase 1b/2a Randomized, Double-Blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tole
NCT02290340
MedImmune LLCPhase 1
CompletedA Prospective, Epidemiological Study to Assess the Disease Burden of Respiratory Syncytial Virus Associated, S
NCT01995175
GlaxoSmithKlineN/A
CompletedA Study in Belgian Children Hospitalized With Respiratory Syncytial Virus Related Acute Respiratory Infections
NCT02133092
Janssen Research & Development, LLC
CompletedA Study in Japanese Children Hospitalized With Respiratory Syncytial Virus Related Lower Respiratory Tract Inf
NCT02132923
Janssen R&D Ireland
TerminatedCough Assist in Bronchiolitis
NCT01757496
University Hospital, AntwerpN/A
CompletedMEDI-557 Adult Dosing
NCT01562938
MedImmune LLCPhase 1
CompletedSofia RSV FIA Field Study
NCT01734668
Quidel Corporation
CompletedRespiratory Events Among Premature Infants
NCT00889070
MedImmune LLC
UnknownComparison of Nylon Flocked Swabs and Saline Aspirates for Detection Respiratory Viruses
NCT00613184
Kern Medical CenterN/A
CompletedRSV Disease in the Elderly
NCT00246480
National Institute of Allergy and Infectious Diseases (NIAID)
CompletedRSV Challenge in Healthy Adults
NCT00100373
National Institute of Allergy and Infectious Diseases (NIAID)N/A
No Longer AvailablePre-Approval Access to JNJ-53718678 for the Treatment of Respiratory Syncytial Virus (RSV) Infection in (a) Im
NCT04221412
Janssen Sciences Ireland UC